Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Blueprint Medicines Corporation (the Company) from time to time
presents and/or distributes to the investment community at
various industry and other conferences slide presentations to
provide updates and summaries of its business. The Company is
posting to the Investors portion of its website at
http://ir.blueprintmedicines.com/a copy of its current corporate
slide presentation. These slides are attached to this Current
Report on Form 8-K as Exhibit 99.1. The Company undertakes no
obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is intended to be
furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Blueprint Medicines Corporation (NASDAQ:BPMC) Recent Trading Information

Blueprint Medicines Corporation (NASDAQ:BPMC) closed its last trading session up +1.84 at 41.98 with 875,326 shares trading hands.